The Future of COPD Care: Viz.ai Partners with Regeneron and Sanofi
COPD, or Chronic Obstructive Pulmonary Disease, is a debilitating lung condition that affects millions of people worldwide. In an effort to improve the diagnosis and management of COPD patients, AI-backed imaging and care coordination company Viz.ai has teamed up with biotechnology company Regeneron and biopharmaceutical company Sanofi to deploy and study an AI-enabled workflow tool specifically designed for COPD.
Viz.ai: Revolutionizing Healthcare with AI
Viz.ai is a leading provider of AI-powered healthcare solutions, offering a care coordination platform equipped with over 50 FDA-cleared algorithms. These algorithms analyze medical imaging data to provide valuable insights for diagnosis, streamline workflows, and assist healthcare providers in making informed treatment decisions. Viz.ai’s suite of AI-enabled tools covers a wide range of specialties, including neurology, trauma, cardiology, radiology, and vascular care.
The Partnership: Advancing COPD Care with AI
Through their collaboration, Sanofi and Regeneron will support Viz.ai in studying the effectiveness of its Viz COPD Module. This innovative tool leverages AI and electronic health record data, incorporating natural language processing to detect and manage high-risk COPD patients. By harnessing the power of AI, the aim is to improve access to care and enhance patient outcomes for individuals suffering from this chronic respiratory condition.
“At Sanofi, we’re excited to collaborate with Viz.ai to address unmet needs in COPD care through the use of AI,” said Dr. Paul Rowe, ATSF and head of medical and specialty care at Sanofi. “By studying the impact of the Viz COPD module, we hope to streamline workflows and ultimately improve patient outcomes in a disease that is often overlooked in comparison to other noncommunicable diseases.”
The Larger Trend: Viz.ai’s Continued Innovations in Healthcare
This partnership with Sanofi and Regeneron is just the latest in a series of collaborations for Viz.ai. Earlier this year, the company joined forces with Guardant Health to address challenges in lung cancer care using AI and genomics. In addition, Viz.ai has partnered with Microsoft to integrate its AI models into the tech giant’s Precision Imaging Network, aimed at enhancing clinical workflows for radiologists.
Other notable collaborations include alliances with Cleerly for heart attack prediction and the Addario Lung Cancer Medical Institute for lung cancer research. Viz.ai has also signed a multiyear agreement with Bristol Myers Squibb to release an AI-enabled algorithm and software for provider workflow.
In 2022, Viz.ai secured $100 million in Series D funding, bringing its valuation to $1.2 billion. This significant investment underscores the growing recognition of Viz.ai’s pioneering work in the field of AI-driven healthcare solutions.
